0001225208-20-011150.txt : 20200901 0001225208-20-011150.hdr.sgml : 20200901 20200901202630 ACCESSION NUMBER: 0001225208-20-011150 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20200828 FILED AS OF DATE: 20200901 DATE AS OF CHANGE: 20200901 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BAKER G LEONARD JR CENTRAL INDEX KEY: 0001201715 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-50679 FILM NUMBER: 201155504 MAIL ADDRESS: STREET 1: 755 PAGE MILL ROAD, SUITE A-200 CITY: PALO ALTO STATE: CA ZIP: 94304-1005 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CORCEPT THERAPEUTICS INC CENTRAL INDEX KEY: 0001088856 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770487658 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 149 COMMONWEALTH DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650.688.8803 MAIL ADDRESS: STREET 1: 149 COMMONWEALTH DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 4 1 doc4.xml X0306 4 2020-08-28 0001088856 CORCEPT THERAPEUTICS INC CORT 0001201715 BAKER G LEONARD JR 755 PAGE MILL ROAD, SUITE A-200 PALO ALTO CA 94304-1005 1 Common Stock 2020-08-28 4 P 0 20444.0000 12.4835 A 3135237.0000 I By Ltd Partnership Common Stock 2020-09-01 4 P 0 25807.0000 12.4976 A 3161044.0000 I By Ltd Partnership Common Stock 996838.0000 D Common Stock 955055.0000 I By Trust The purchases reported in this Form 4 were matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, with the sales of shares by the reporting person, to the extent of the reporting person's pecuniary interest therein, at prices ranging from $15.76 to $15.7602, inclusive, on May 28, 2020. The reporting person has agreed to pay to the Issuer the profit realized by the reporting person in connection with the short-swing transaction, less transaction costs. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.43 to $12.50, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the general partner. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.45 to $12.50, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. The reporting person shares pecuniary interest in these shares with other individuals pursuant to a contractual relationship. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares. Shares held by a trust of which the reporting person is a trustee. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in the trust. cortglbnew.txt /s/ Kanwalpreet S. Kalra, by power of attorney 2020-09-01 EX-24 2 cortglbnew.txt POWER OF ATTORNEY Know all by these presents, that the undersigned hereby authorizes Christopher J. Basso or Kanwalpreet S. Kalra to execute for and on behalf of the undersigned Forms 3, 4, and 5, and any Amendments thereto for Corcept Therapeutics, Inc. (the "Company"), and cause such form(s) to be filed with the United States Securities and Exchange Commission pursuant to Section 16(a) of the Securities Act of 1934, relating to the undersigned's beneficial ownership of securities in the Company. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney- in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such a capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934. This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of, and transactions in, securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact. In witness whereof, the undersigned has caused this Power of Attorney to be executed as of this 28th day of August, 2020. /s/ G. Leonard Baker, Jr.